Poolbeg Pharma upbeat on preliminary influenza drug results

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.15
+3.88 (1.89%)
AAPL  272.49
+6.31 (2.37%)
AMD  212.96
+16.36 (8.32%)
BAC  50.30
-0.77 (-1.51%)
GOOG  311.31
-0.38 (-0.12%)
META  638.63
+1.38 (0.22%)
MSFT  386.18
+1.70 (0.44%)
NVDA  192.95
+1.40 (0.73%)
ORCL  144.76
+3.45 (2.44%)
TSLA  404.48
+4.65 (1.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.